menu search

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting dose U.S. Commercial launch expected Q1 2023 Company to host conference call on Thursday, December 29, 2022 at 8:30 AM ET A Media Snippet accompanying […] The post TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) appeared first on ForexTV... Read More
Posted: Dec 28 2022, 18:48
Author Name: forextv
Views: 110172

Search within

Pages Search Results: